Keith Ward
Kuria Therapeutics Achieves Preclinical Proof-of-Concept for Age-Related Macular Degeneration
- Expands development pipeline with planned Phase 2 clinical trial for dry AMD Kuria Therapeutics, a pharmaceutical company developing a...
top of page
Search
Keith Ward
Kuria Granted Exclusive Worldwide Rights to Novel Nrf2 Activator
Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2...
bottom of page